Data Zoo Named a Leader in Liminal’s Link Index for Age Verification
11.3.2025 14:00:00 CET | Business Wire | Press release
Data Zoo, a global leader in identity verification and fraud prevention solutions, proudly announces its recognition as a leading vendor in the Liminal’s Link Index for Age Verification. Evaluated for its performance across strategy, product capabilities, and market presence, Data Zoo has been identified as a top provider meeting the growing demands of the age assurance landscape.
Liminal’s Link Index cites Data Zoo’s exceptional global coverage, advanced data privacy compliance, and seamless user experience as key factors for its leadership position. With businesses and regulators increasingly prioritizing robust and reliable age verification, Data Zoo’s innovative solutions help organizations address regulatory compliance, manage fraud risks, and maintain public trust.
“Age verification is at the core of creating safer and compliant digital spaces,” explains Charlie Minutella, CEO at Data Zoo. “Being named a leader by Liminal reinforces the value of our data-centric approach and commitment to helping businesses protect their customers while adhering to evolving global regulations.”
Age Verification Expertise That Sets Data Zoo Apart
According to Liminal’s Link Index, vendors were assessed on their ability to address critical challenges in the age verification market, including data privacy concerns, scalability, and innovation. Data Zoo excelled in several areas:
- Global Coverage: Leveraging access to authoritative databases across 50+ countries, Data Zoo provides seamless age verification for a diverse and global user base.
- Accuracy and User Experience: Delivering a 96% automated match rate, the platform ensures a frictionless experience for end-users while maintaining high verification accuracy.
- Innovation: With a privacy-first strategy, Data Zoo stays ahead by enhancing fraud detection capabilities using advanced AI-driven signals, ensuring protection against emerging threats like synthetic identities and deepfakes.
Meeting the Needs of a Growing Market
The age verification market is expected to grow significantly, reaching $10.4 billion by 2029, driven by increasing adoption across regulated and unregulated sectors. Data Zoo’s scalable, user-friendly solutions are uniquely positioned to address this demand, offering businesses the tools to adapt to regulatory shifts while protecting their customers.
“With global regulations evolving rapidly, companies need solutions that balance compliance with user experience,” adds Minutella. “Data Zoo is at the forefront, empowering businesses to ensure secure and compliant operations while building customer trust. This commitment is reflected in Liminal’s exceptional rating in the User Experience category.”
About Data Zoo
Data Zoo provides identity verification data that enables financial institutions, payment platforms, and fintechs to confidently verify consumers and business identities in over 170 jurisdictions using a diverse set of authoritative data sources. Data Zoo’s direct access to international data sources and advanced data sequencing presents companies with a global, efficient, and secure alternative to KYC/KYB verification and compliance.
Leading global financial institutions, payment providers, and fintechs trust Data Zoo to verify millions of customers while minimizing fraud and risk. Headquartered in New Jersey, Data Zoo has offices in Amsterdam, Australia, New Zealand, the Philippines, and Singapore. For more information, visit: www.datazoo.com.
For more information, visit www.datazoo.com or contact our media team below.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311750263/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom